Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIB, Randomized, Double-Blinded, Placebo-Controlled Study of Low Dose Cytarabine and Lintuzumab Compared to Low Dose Cytarabine and Placebo in Patients 60 Years of Age and Older With Previously Untreated AML

NCT00528333 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT00528333
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00528333 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIB, Randomized, Double-Blinded, Placebo-Controlled Study of Low Dose Cytarabine and Lintuzumab Compared to Low Dose Cytarabine and Placebo in Patients 60 Years of Age and Older With Previously Untreated AML
Lead sponsor
Seagen Inc.
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2007
Completion date
August 31, 2010
Enrollment
211 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia